ClinicalTrials.gg
CompletedNCT00272012Updated Dec 7, 2009

OPAL - Insulin Glulisine, Diabetes Mellitus

A Phase 3 interventional study of Insulin glulisine in Diabetes Mellitus Type 2, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
5th of 25
396 · median 281
Started
2004
with 5 others
Phase 3
8 of 26
none open now
Registered
6th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2004, is one of 8 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Primary objective:

The primary study objective is to compare efficacy of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of change in HbA1c, from baseline to endpoint for the individual patient. The aim of the study is to demonstrate two-sided equivalence between the two therapy regimens receiving two different injection timing of Insulin glulisine.

Secondary objective:

Secondary study objectives are to compare efficacy and safety of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of:

  • Change of fasting-, pre-/2h-postprandial-, mean daily and nocturnal blood glucose (baseline to endpoint)
  • Change of fasting plasma glucose (baseline to endpoint)
  • Response rate: Responders will be those patients with HbA1c smaller than 7.0% at study endpoint
  • Insulin dose (rapid-acting, basal and total daily doses)
  • Weight, body-mass index
  • Hypoglycemic events
  • Adverse events
03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes mellitus, previously treated with combination therapy of insulin glargine + OAD (maximal tolerated dose / approved in combination with insulin according to local SPCs (Summary of Product Characteristics), not including use of a-glucosidase inhibitors) for at least 3 months
  • Pre-screening value greater/equal 7% - smaller/equal 9%
  • FBG (Fasting Blood Glucose) smaller/equal 120 mg/dl (6.6 mmol/l)
  • Women are either not of (surgically sterile, or for more than 2 years) or are not pregnant and agree to use a reliable measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide.
  • Ability and willingness to perform blood glucose monitoring using the sponsor-provided blood glucose meter and subject diary at home

Exclusion criteria

Exclusion criteria:

  • More than two FBG greater 120 mg/dl (6.6 mmol/l) as measured on 5 consecutive days before visit II
  • Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation)
  • cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
  • Known impaired hepatic and renal function
  • History of drug or alcohol abuse
  • History of to insulin or insulin analogues or any of the in the Insulin glulisine formulation
  • Treatment with any drug in the last month before visit I
  • Pregnant or breast-feeding women, or women planning to become pregnant during the study
  • Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Night shift workers if they are unable to comply with the treatment regimen
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
396 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c.

    Time frame: from baseline to study endpoint.

Secondary outcomes

  1. Change of pre-, 2 h postprandial and nocturnal blood glucose values

    Time frame: 8-point profile

  2. Fasting blood glucose

    Time frame: 8-point blood glucose profile values

  3. Responder rate HbA1c smaller 7 %

    Time frame: at study endpoint

  4. Insulin dose

    Time frame: rapid-acting, basal and total daily doses

  5. Weight, BMI

    Time frame: study follow-up

  6. Hypoglycemic events

    Time frame: study follow-up

  7. Adverse events.

    Time frame: study follow-up

07

Study locations

1 site
  • Sanofi-Aventis
    Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a primary completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2006
First posted
Jan 4, 2006
Start
Jul 2004
Primary completionActual
Sep 2006
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00272012
Lead sponsor
Sanofi
First posted
Jan 4, 2006
Start date
Jul 2004
Primary completion
Sep 2006
Last update
Dec 7, 2009

Study contacts

Wolfgang Landgraf, Dr.
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion